News for Nippon Shinyaku Co., Ltd. (4516.T)

**media[595441]**

**media[583704]**

Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy

--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Ass

**media[564244]**

Company to Host Conference Call, March 19, 2025 at 4:30 p.m. ET SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( CAPR), a biotechnology

PR NewswirePARAMUS, N.J., March 10, 2025 PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Lt

**media[560229]**

**media[556676]**

**media[536796]**

**media[524739]**

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payme

**media[504255]**

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( CAPR), a biotechnology company developing transformative cell and exosome-based therapeut

**media[481372]**

Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular dystrophy in the European region SAN D

**media[465445]**

**media[464345]**